The use of atypical antipsychotics beyond psychoses: Efficacy of quetiapine in bipolar disorder

Neuropsychiatric Disease and Treatment

Volumn 2, Issue 2, 2006, Pages 139-148

  Mundo, Emanuela ^a   Cattaneo, Elisabetta ^a   Zanoni, Silvia ^a   Altamura, A Carlo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Atypical antipsychotics; Bipolar disorder; Quetiapine; Treatment

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CHLORPROMAZINE; CLOMIPRAMINE; CLOZAPINE; FLUOXETINE; GABAPENTIN; GLUTAMIC ACID; HALOPERIDOL; KETOCONAZOLE; LITHIUM SALT; MIRTAZAPINE; MOOD STABILIZER; OLANZAPINE; PAROXETINE; PHENYTOIN; PLACEBO; QUETIAPINE; RISPERIDONE; THIORIDAZINE; VALPROATE SEMISODIUM; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE;

ADD ON THERAPY; AKATHISIA; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BODY WEIGHT DISORDER; CLINICAL TRIAL; DATA ANALYSIS; DATA BASE; DIABETES MELLITUS; DOPAMINERGIC ACTIVITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESPONSE; DRUG SELECTIVITY; DRUG USE; DYSLIPIDEMIA; HUMAN; HYPERLIPIDEMIA; LONG TERM CARE; LOW DRUG DOSE; MANIA; MEDICAL LITERATURE; MESOLIMBIC DOPAMINERGIC SYSTEM; MONOTHERAPY; OBESITY; PSYCHOSIS; RECURRENCE RISK; REMISSION; RETROSPECTIVE STUDY; REVIEW; SHORT COURSE THERAPY; WEIGHT GAIN;

EID: 33745929014     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/nedt.2006.2.2.139     Document Type: Review

References (78)

1. Alderfer BS, Allen MH.2003. Treatment of agitation in bipolar disorder across life cycle. J Clin Psychiatry, 64 (Suppl 4):3-9.
2. Allison DB, Mentore JL, Heo M et al. 1999. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry, 156: 1686-6.
3. Altamura AC. 1996. Novel antipsychotics and the problem of clinical stabilization in schizophrenia: are they "stabilizers" rather than typical compounds? Int Clin Psychopharmacol, 11:153-5.
4. Altamura AC, Salvadori D, Madaro D, et al. 2003. Efficacy and tolerability of quetiapine in the treatment of bipolar disorder:preliminary evidence from 12-month open-label study. J Affect Disord, 76:267-71.
5. Altamura AC, Russo M, Vismara S, et al. 2004. Comparative evaluation of olanzapine efficacy in the maintenance treatment of Bipolar Disorder. J Clin Psychopharmacol, 24:454-6.
6. [APA) American Psychiatric Association. 2002. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 159(Suppl 4):1-50.
7. Arvanitis LA, Miller BG. 1997. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia:a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry, 42:233-46.
8. Bahk WM, Yoon BH, Lee KU, et al. 2004. Combination of mood stabilizers with quetiapine for treatment of acute bipolar disorder:an open label study. Hum Psychopharmacol, 19:181-5.
9. Berk M, Dodd S. 2003. Recent developments in the treatment of bipolar disorders. Expert Opin Investig Drugs, 12:1621-32.
10. Berk M, Dodd S. 2005. Efficacy of atypical antipsychotics in bipolar disorder. Drugs, 62:257-69.
11. Biancosino B, Marmai L, Facchi A, et al 2003. Quetiapine may induce mania:a case report. Can J Psychiatry, 48:349-350.
12. Borison RL, Arvanitis LA, Miller BG. 1996. ICI 204, 636, an atypical antipsychotic:efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. US SEROQUEL Study Group. J Clin Psychopharmacol, 16:158-69.
13. Bourin M, Lambert O, Guitton B. 2005. Treatment of acute mania from clinical trials to recommendations for clinical practice. Hum Psychopharmacol, 20:15-26.
14. Bowden CL, Grunze H, Mullen J, et al. 2005. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry, 66:11-121.
15. Calabrese JR, Shelton MD, Rapport DJ, et al. 2001. Current research on rapid cycling bipolar disorder and its treatment. J Affect Disord, 67:241-55.
16. Calabrese JR, Macfadden W, McCoy R, et al. 2004. Double-blind, placebo-controlled study of quetiapine in bipolar depression [poster]. 157th Annual Meeting of the American Psychiatric Association. 2004 May 1-6; New York, NY, USA.
17. Carta MG, Hardoy MC, Garofalo A, et al. 2004. Combination quetiapine therapy in the long-term treatment of patients with refractory bipolar I disorders [abstract]. The 157th Annual Meeting of the American Psychiatric Association. 2004 May 1-6; New York, NY, USA.
18. DelBello MP, Schwiers ML, Rosenberg HL, et al. 2002. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Child Adolesc Psychopharmacol, 41:1216-23.
19. De Vane CL, Nemeroff CB. 2001. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet, 40:509-22.
20. Dunayevich E, Strakowski SM. 2000. Quetiapine for treatment-resistant mania. Am J Psychiatry, 157:1341.
21. Esparon J, Kolloori J, Naylor GJ, et al. 1986. Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients. Br J Psychiatry, 148:723-5.
22. Garver DL. 2000. Review of quetiapine side-effects. J Clin Psychiatry, 61(Suppl 8):31-33.
23. Ghaemi S, Goldberg J, Ko J, et al. 2002. Quetiapine treatment of rapid-cycling bipolar disorder: an open prospective study. Int J Neuropsychopharmacol, 5(Suppl 1):S110.
24. Goldstein JM. 1999. Quetiapine fumarate (Seroquel). A new atypical antipsychotic. Drugs Today (Barc), 35:193-210.
25. Grimm SW, Stains KR, Bui K. 1997. In vitro prediction of potential metabolic drug interaction for seroquel (quetiapine) [abstract). The 150th American Psychiatric Association Annual Meeting. 1997 May 17-22; San Diego, CA, USA.
26. Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry, 23:56-62.
27. Kane JM. 1996. Schizophrenia. N Engl J Med, 334:34-41.
28. Kapur S, Langlois X, Vinken P, et al. 2002. The differential effect of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition:a pharmacological analysis in rats. J Pharmacol Exp Ther, 302:1129-34.
29. Kasper S, Stamenkovic M, Letmaier M, et al. 2002. Atypical antipsychotics in mood disorders. Int Clin Psychopharmacol, 17 (Suppl 3):S1-10.
30. Keck PE Jr, Marcus R, Tourkodimitris S, et al. 2003a. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry, 160:1651-8.
31. Keck PE Jr, Versiani M, Potkin S et al. 2003b. Ziprasidone in the treatment of acute bipolar mania:a three-week, placebo-controlled, double blind, randomized trial. Am J Psychiatry, 160:741-8.
32. Keck PE Jr. 2005. The role of second-generation antipsychotic monotherapy in the rapid control of acute bipolar mania. J Clin Psychiatry, 66(Suppl 3):5-11.
33. Ketter TA, Wang PW, Nowakowska C, et al. 2004. New medication treatment options for bipolar disorders. Acta Psychiatr Scand, 110(Suppl 422):18-33.
34. Khanna S, Vieta E, Lyons B, et al. 2003. Risperidone monotherapy in acute bipolar mania (abstract P108). Bipolar Disord, 5 (Suppl 1):60.
35. Lane HY, Lin YC, Chang WH. 1998. Mania induced dy risperidone:dose related? J Clin Psychiatry, 59:85-6.
36. Lykouras L, Oulis P, Hatzimanolis J. 2003. Manic symptoms associated with quetiapine treatment. Eur Neuropsychopharmacol, 13:135-6.
37. Lyseng-Williamson KA, Perry CM. 2004. Aripiprazole in acute mania associated with bipolar I disorder. CNS Drugs, 18:367-76.
38. Macfadden W, Calabrese JR, McCoy R, et al. 2004. Antianxiety effects analysis of quetiapine in bipolar depression [abstract]. The 157th Annual Meeting of the American Psychiatric Association. 2004 May 1-6; New York, NY, USA.
39. Manji HK, Lenox RH. 2000. The nature of bipolar disorder. J Clin Psychiatry, 61 (Suppl 13):42-57.
40. McConville BJ, Arvanitis LA, Thyrum PT, et al. 2000. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate:an open-label trial in adolescents with psychotic disorders. J Clin Psychiatry, 61:252-60.
41. McIntyre R, Brecher M, Paulsson B, et al. 2005. Quetiapine or haloperidol as monotherapy for bipolar mania:a 12-week, double-blind, randomized, parallel group, placebo-controlled trial. Eur Neuropsychopharmacol, 15: 573-85.
42. Melkersson KI, Hulting AL, Brismar KE. 2000. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry, 61:742-9.
43. Mundo E, Walker M, Cate T, et al. 2001. The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder.Preliminary findings. Arch Gen Psychiatry, 58:539-44
44. Mundo E, Tharmalingham S, Neves-Pereira M, et al. 2003. Evidence that the N-methyl-D-asparate subunit-1 receptor gene (GRIN1) confers susceptibility to Bipolar Disorder. Mol Psychiatry, 8:241-5.
45. Mundo E, Cattaneo E, Russo M, Altamura AC. 2006. Clinical variables related to antidepressant-induced mania in Bipolar Disorder. J Affect Disord. In press.
46. Nasrallah HA, Newcomer JW. 2004. Atypical antipsychotics and metabolic dysregulation:evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol, 24 (Suppl 1):S7-14.
47. Pae CU, Kim TS, Kim JJ, et al. 2005. Long-term treatment of adjunctive quetiapine for bipolar mania. Prog Neuropsychopharmacol Biol Psychiatry, 29:763-6.
48. Pacchiarotti I, Manfredi G, Kotzalidis GD, et al 2003. Quetiapine-induced mania (letter). Aust NZ J Psychiatry, 37:626.
49. Post RM, Frye MA, Leverich GS et al. 1998. The role of complex combination therapy in the treatment of refractory bipolar illness. CNS Spectrums, 3:66-86.
50. Post RM, Weiss S. 1999. Neurobiological models of recurrence in mood disorders. In Neurobiology of mental illness. Charney DS, Nestler EJ, Bunney B (eds). New York: Oxford University Pr.
51. Potkin SG, Thyrum PT, Alva G, et al. 2002. The safety and pharmacokinetics of quetiapine when co-administered with haloperidol, risperidone, or thioridazine. J Clin Psychopharmacol, 22:121-30.
52. Purdon SE, Malla A, Labelle A et al. 2001. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci, 26:137-49.
53. Rachid F, Bertschy G, Bondolfi G, et al. 2004. Possibile induction of mania or hypomania by atypical antipsychotics:an update review of reported cases. J Clin Psychiatry, 65:1537-45.
54. Richelson E. 1999. Receptor pharmacology of neuroleptics:relation to clinical effects. J Clin Psychiatry, 60 (Suppl 10):5-14.
55. Sachs GS, Chengappa KNR, Suppes T, et al. 2004. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomised, double-blind, placebo-controlled study. Bipolar Disord, 6:213-23.
56. Sajatovic M, Brescan DW, Perez DE et al. 2001. Quetiapine alone and added to mood-stabilizer for serious mood disorders. J Clin Psychiatry, 62:728-32.
57. Sajatovic M, Mullen JA, Sweitzer DE. 2002. Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. J Clin Psychiatry, 63:1156-63.
58. Schmidt AW, Lebel LA, Howard HR Jr, et al. 2001. Ziprasidone:a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol, 425:197-201.
59. Small JG, Hirsch SR, Arvanitis LA et al 1997. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry, 54:549-57.
60. Smulevich AB, Khanna S, Eerdekens M, et al. 2005. Acute and continuation risperidone monotherapy in bipolar mania:a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol, 15:75-84.
61. Sokolski KN, Denson TF. 2003. Adjunctive quetiapine in bipolar patients partially responsive to lithium or valproate. Prog Neuropsychopharmacol Biol Psychiatry, 27:863-6.
62. Spearing MK, Post RM, Leverich GS, et al. 1997. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP):the CGI-BP. Psychiatry Res, 73:159-71.
63. Tascedda F, Lovati E, Blom JMC, et al. 1999. Regulation of ionotropic glutamate receptors in the rat brain in response to the atypical antoipsychotic Seroquel (quetiapine fumarate). Neuropsychopharmacol, 21:211-17.
64. Tascedda F, Blom JMC, Brunello N, et al. 2001. Modulation of glutamate recetors in response to the novel antipsychotic olanzapine in rats. Biol Psychiatry, 50:117-22.
65. Thyrum PT, Wong YWJ, Yeh C. 2000. Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment. Prog Neuropsychopharmacol Biol Psychiatry, 24:521-33.
66. Tohen M, Jacobs TG, Grundy SL et al. 2000. Efficacy of olanzapine in acute bipolar mania:a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group. Arch Gen Psychiatry, 57:841-9.
67. Tohen M, Vieta E, Calabrese J, et al. 2003. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry, 60:1079-88.
68. Van der Heiden FMMA, Tuinier S, Fekkes D, et al. 2004. Atypical antipsychotics and the relevance of glutamate and serotonin. Eur Neuropsychopharmacol, 14:259-65.
69. Vieta E. 1999. Abordaje Actual de Los Trastornos Bipolares. Barcelona:Masson.
70. Vieta E. 2005. Mood stabilization in the treatment of bipolar disorder:focus on quetiapine. Hum Psychopharmacol Clin Exp, 20:225-236.
71. Vieta E, Parramon G, Padrell E, et al. 2002. Quetiapine in the treatment of rapid cycling bipolar disorder. Bipolar Disord, 4:335-40.
72. Vieta E, Goikolea JM. 2005. Atypical antipsychotics:newer options for mania and maintenance therapy. Bipolar Disord, 7 (Suppl 4):21-33.
73. Vieta E, Mullen J, Brecher M, et al. 2005. Quetiapine monotherapy for mania associated with bipolar disorder combined analysis of two international, double-blind, randomised, placebo-controlled studies. Curr Med Res Opin, 21:923-34.
74. Wirshing DA, Spellberg BJ, Erhart SM et al. 1998. Novel antipsychotics and new onset diabetes. Biol Psychiatry, 44:778-83.
75. Wong YW, Yeh C, Thyrum PT. 2001. The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine. J Clin Psychopharmacol, 21:89-93.
76. Yatham LN. 2003. Efficacy of atypical antipsychotics in mood disorders. J Clin Psychopharmacol, 23 (Suppl 1):S9-14.
77. Yatham LN, Paulsson B, Mullen J, et al. 2004. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J Clin Psychopharmacol, 24:599-606.
78. Young RC, Biggs JT, Ziegler VE, et al. 1978. A rating scale for mania:reliability, validity and sensibility. Br J Psychiatry, 113: 429-35.